mProX™ Human NUAK2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human NUAK2 Stable Cell Line (S01YF-1023-PY33). Click the button above to contact us or submit your feedback about this product.
Taylor Brown (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Casey Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 NuAK2 knockdown decreased the number of cells in SM2-1 and C32 cells.
A cell proliferation analysis demonstrated a noteworthy decrease in the growth of C32 and SM2-1 melanoma cells following the silencing of NUAK2 using shNUAK2 (with p-values of 0.0165 and < 0.0001, respectively).
Ref: Namiki, Takeshi, et al. "NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK activation." Cancer research 75.13 (2015): 2708-2715.
Pubmed: 25832654
DOI: 10.1158/0008-5472.CAN-13-3209
Research Highlights
Nojima, Kohei. et al. "Activated Akt expression is associated with the recurrence of primary melanomas and further refines the prognostic and predictive values for relapse in acral melanomas." Pigment cell & melanoma research, 2023.
A deficiency in PTEN has been shown to activate phospho-Akt at serine 473 (p-Akt) and contribute to the development of melanomas through NUAK2 amplification. To determine the prognostic value of p-Akt and/or NUAK2 expression in melanoma patients, primary tumors from 168 patients with acral, Low-cumulative sun damage (CSD), and High-CSD melanomas were immunohistochemically examined. Results showed p-Akt expression in 32.1%, 68.4%, and 55.6% of acral, Low-CSD, and High-CSD melanomas, respectively, while NUAK2 expression was found in 46.4%, 76.3%, and 50.0%, respectively. A negative correlation was observed between either p-Akt or NUAK2 expression and relapse-free survival (RFS) in primary melanoma patients and those with acral melanoma. Multivariate analyses revealed a significant impact of p-Akt on RFS, while NUAK2 did not have a significant effect. Subset analyses showed that p-Akt expression was associated with lower RFS in patients with acral melanomas. These findings suggest that p-Akt expression can serve as a predictor for relapse in patients with primary melanomas and specifically in those with acral melanomas.
Nojima, Kohei. et al. "Activated Akt expression is associated with the recurrence of primary melanomas and further refines the prognostic and predictive values for relapse in acral melanomas." Pigment cell & melanoma research, 2023.
Pubmed:
37596787
DOI:
10.1111/pcmr.13119
Guo, Zijun; G, Lin. "OTUD7B deubiquitinates and stabilizes YAP1 to upregulate NUAK2 expression, thus accelerating gastric cancer procession." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023.
Gastric cancer (GC) is a prevalent malignancy globally. The ovarian tumor protein superfamily plays a vital part in tumor growth progression and includes the deubiquitinase (DUB) ovarian tumor domain-containing 7B (OTUD7B), which has been detected in various cancers. However, its function in GC remains unclear.
Guo, Zijun; G, Lin. "OTUD7B deubiquitinates and stabilizes YAP1 to upregulate NUAK2 expression, thus accelerating gastric cancer procession." Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023.
Pubmed:
37429790
DOI:
10.1016/j.dld.2023.06.026
